NCT05972616

Natural Matrix Protein™ (NMP™) in Interbody Lumbar Fusion

A Single-center Review of the Performance of Induce Biologics NMP™ in Patients Who Have Undergone Interbody Fusion for Degenerative Disease of the Lumbar Spine

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 53 (actual)
• Sponsor: Induce Biologics USA Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The objective of this study is to evaluate the performance of Induce Biologics NMP™ when used to promote interbody fusion for degenerative disease of the lumbar spine.

Detailed description

The study involves a retrospective review of patients' medical records and prospective collection of CT scans, X-rays, and patient centered outcome questionnaires. The study population will include up to 135 patients of the Spine Institute of Louisiana (SIL) who have been treated with Induce Biologics NMP™ during a lumbar interbody fusion. All subjects who meet all inclusion criteria and do not meet any exclusion criteria will be included in the study. There will be a single Prospective Visit in this study. This visit will be scheduled at the 12-month (± 2 mo) post-surgery time point.

Conditions

• Degenerative Disc Disease

Interventions

Type	Name	Description
BIOLOGICAL	Natural Matrix Protein (NMP)	human bone allograft

Timeline

• Start date: 2023-08-01
• Primary completion: 2024-02-21
• Completion: 2024-02-21
• First posted: 2023-08-02
• Last updated: 2025-10-14

Locations

1 site across 1 country: United States